1 Association of Free Triiodothyronine with Long-Term Prognosis in Hypertrophic

2 cardiomyopathy patients with HFpEF: A Dual center research study

- 3 Xiangbin Meng¹*; Jing-Jia Wang¹*; Jun Gao¹*; Kuo Zhang²*; Wen Jun²; Xu-Liang Wang¹;
- 4 Yuan-Geng-Shuo Wang¹; Ji-Lin Zheng²; Yu-Peng Liu³; Jing-Jing Song²; Jie Yang¹; Yi-Tian
- 5 Zheng¹; Chen Li¹; Wen-Yao Wang^{1#}; Chunli Shao^{1#}; Yi-Da Tang^{1#}
- 6 ¹Department of Cardiology and Institute of Vascular Medicine, Peking University Third
- 7 Hospital, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education,
- 8 Beijing, China.
- 9 ²Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital,
- 10 National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and
- 11 Peking Union Medical College, Beijing 100037, China.
- ³Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy
- 13 of Medical Sciences), Southern Medical University, Guangzhou, China
- 14 * These authors contributed equally to this study.
- 15 Corresponding to: Yi-Da Tang, MD, PhD, Chunli Shao, MD, PhD, and Wen-Yao Wang
- 16 MD, PhD
- 17 Abbreviated Title: Free T3 and Prognosis in HCM Patients with HFpEF: A Dual Center Study
- 18 *Key words:* HFpEF, prognosis, FT3 levels, prognostic factors, all-cause mortality and cardiac
- 19 transplantation.
- 20 *Word count:* 198 (abstract); 3501 (excluding abstract, figure legends, and references)
- 21 Number of figures and tables: 5
- 22 Conflict of interest statement
- 23 The authors have no potential conflict of interest to declare.

- 24 Corresponding to: Yi-Da Tang, MD, PhD, Chunli Shao, MD, PhD, and Wen-Yao Wang,
- 25 MD, PhD
- 26 Yi-Da Tang, MD, PhD, Department of Cardiology and Institute of Vascular Medicine, Peking
- 27 University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of
- 28 Education, Beijing, China. No.49 Huayuanbei Road, Beijing 100191, China (Email:
- 29 <u>tangyida@bjmu.edu.cn</u>).
- 30 Chunli Shao, MD, PhD, Department of Cardiology and Institute of Vascular Medicine, Peking
- 31 University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of
- 32 Education, Beijing, China. No.49 Huayuanbei Road, Beijing 100191, China (Email:
- 33 chunlishao@126.com).
- 34 Wen-Yao Wang, MD, PhD, Department of Cardiology and Institute of Vascular Medicine,
- 35 Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science,
- 36 Ministry of Education, Beijing, China. No.49 Huayuanbei Road, Beijing 100191, China (Email:
- 37 wangwy@bjmu.edu.cn).
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45

46 Abstract

47	Objective: The objective of this study was to identify prognostic factors in Hypertrophic
48	cardiomyopathy patients with HFpEF, with a particular focus on the role of FT3 levels.
49	Research Design and Methods: We conducted a retrospective cohort study of 992 patients
50	with HFpEF who were admitted to our two medical centers between 2009 and 2019. We
51	collected demographic and clinical data, including FT3 levels, and conducted univariate and
52	multivariate Cox analyses, KM survival curve analysis, and RSC curve analysis to identify
53	prognostic factors and evaluate the non-linear predictive value of FT3.
54	Results: We found that age, atrial fibrillation, and NT-proBNP levels were all significant
55	prognostic factors in patients with heart failure. Additionally, FT3 levels were a significant
56	independent predictor of all-cause mortality and cardiac transplantation. Patients with lower
57	FT3 levels had worse long-term prognoses, and the critical value of FT3 was 2.885.
58	Conclusions: Our findings suggest that FT3 levels are an important prognostic factor in
59	patients with heart failure and should be considered when evaluating patient outcomes.
60	Clinicians should monitor FT3 levels and consider interventions to maintain or improve
61	thyroid function in patients with heart failure.
62	Key words: heart failure, prognosis, FT3 levels, prognostic factors, all-cause mortality,
63	cardiac transplantation
64	Article Highlights:
65	• FT3 levels are a significant independent predictor of all-cause mortality and cardiac
66	transplantation in Hypertrophic cardiomyopathy patients with HFpEF
67	• Patients with hypertrophic cardiomyopathy combined with HFpEF have a poorer

- 68 long-term prognosis with lower FT3 levels, with a critical FT3 value of 2.885
- 69 Age, atrial fibrillation, and NT-proBNP levels were also significant prognostic factors in
- 70 Hypertrophic cardiomyopathy patients with HFpEF
- Clinicians should monitor FT3 levels and consider interventions to maintain or improve
- 72 thyroid function in Hypertrophic cardiomyopathy patients with HFpEF.

73 1.Introduction

74	Heart failure (HF) is a chronic and progressive condition in which the heart is unable to pump
75	enough blood to meet the body's needs. It is a major cause of morbidity and mortality
76	worldwide, with an estimated prevalence of 1-2% in the general population. The prognosis of
77	HF is highly variable, and identifying prognostic factors is critical for guiding clinical
78	decision-making and improving patient outcomes. The importance of identifying prognostic
79	factors in HF cannot be overstated. Such factors can help clinicians stratify patients according
80	to their risk of adverse outcomes, tailor treatment plans to individual patients, and monitor
81	disease progression over time. However, despite extensive research in this area, there is still a
82	need to identify new prognostic markers that can improve risk prediction and guide treatment
83	decisions.
84	HF with preserved ejection fraction (HFpEF) is a specific type of HF in which the ejection
85	fraction, or the percentage of blood that is pumped out of the heart with each beat, is normal
86	or only slightly reduced. Patients with HFpEF typically present with symptoms such as
87	shortness of breath, fatigue, and exercise intolerance, and the prevalence of HFpEF is
88	increasing due to the aging population and the high prevalence of comorbidities such as
89	hypertension and diabetes.
90	Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by abnormal
91	thickening of the heart muscle, which can lead to various clinical manifestations including
92	arrhythmias, heart failure, and sudden cardiac death. Previous studies have shown that the
93	prevalence of HFpEF is high in patients with HCM, and HFpEF has been shown to be an
94	independent predictor of adverse outcomes in this population.

95 Thyroid hormones are known to have important effects on the cardiovascular system, 96 including the regulation of heart rate, contractility, and vascular tone. Thyroid hormone 97 profile acts as a fundamental regulator in cardiovascular homeostasis in both physiological 98 conditions and pathological processes ^[1,2]. Abnormal thyroid hormone levels, such as 99 hypothyroidism or hyperthyroidism, have been associated with various cardiovascular 100 diseases including HF. Our previous study, together with other clinical evidence, indicated 101 that thyroid hormone levels, particularly the level of free triiodothyronine (FT3), correlate with exacerbated cardiac function ^[3-6] and hypothyroid status was an independent risk factor 102 103 of adverse events in patients with cardiovascular diseases. The potential mechanism 104 underlying the influence of thyroid hormone levels on cardiovascular disease involves the 105 regulation of gene expression and signaling pathways involved in cardiac hypertrophy, 106 fibrosis, and inflammation^[7,8]. FT3 is a thyroid hormone that plays a critical role in regulating 107 cardiac function, and previous studies have suggested that low FT3 levels are associated with poor outcomes in patients with HF^[8]. However, the relationship between FT3 and prognosis 108 109 of patients with HCM and HFpEF is still not well understood, and further research is needed 110 to elucidate this relationship and identify optimal cutoff values for risk stratification. 111 Given the high prevalence of HFpEF in patients with HCM and the potential role of thyroid 112 hormones in cardiovascular disease, there is a need to identify diagnostic factors that may 113 help predict outcomes in this population. In this study, we aimed to investigate the prognostic 114 value of thyroid hormone levels in patients with HCM and HFpEF, and to explore the 115 potential mechanism underlying this association.

116 2. Research Design and Methods

117 2.1Ethics statement

- 118 The study was in accordance with the ethical guidelines of the declaration of Helsinki and
- 119 China's regulations and guidelines on good clinical practice and was approved by the Ethics
- 120 Committee of the Peking University Third Hospital. Before the start of the study, we received
- 121 written informed consents from all participants.
- 122 2.2 Design, patients, and outcome measure

123 2.2.1 Study Patients

- 124 This study was a two-center, retrospective cohort study. All patients in this study were
- evaluated at two medical centers: the Peking University Third Hospital, and Fuwai Hospital
- 126 (National Center of Cardiovascular Diseases, China). Between October 1, 2009, and
- 127 December 31, 2019, a total of 2802 patients (age>16 years) were diagnosed with HOCM.
- Among them, 187 patients with EF<50% were excluded from this study. In the end, 992
- 129 patients with hypertrophic cardiomyopathy diagnosed with HFpEF were included in this study.
- 130 Patients were divided into three groups according to the FT3 levels: Tertile 1: (FT3<2.77
- 131 pg/mL, n=336), Tertile 2 :(2.77 pg/mL \leq FT3 \leq 3.09 pg/mL, n=335), Tertile 3 (FT3>3.10
- 132 pg/mL, n=321).

133 2.2.2 Diagnosis of HOCM

- 134 The diagnosis of HOCM was based on ^[9-11]: 1, wall thickness \geq 15 mm in one or more LV
- 135 myocardial segments, as measured by any imaging technique (echocardiography, cardiac
- 136 magnetic resonance imaging, or computed tomography); 2, wall thickness (13-14mm) with
- 137 family history, non-cardiac symptoms and signs, electrocardiogram(ECG) abnormalities,
- 138 laboratory tests, and muti-modality cardiac imaging; 3, patients with LV outflow tract

139	obstruction (LVOTO) were based on: dynamic LVOT obstruction due to systolic anterior
140	motion of the mitral valve, with an LVOT gradient \geq 30 mmHg at rest or during physiological
141	provocation such as Valsalva maneuver, standing, and exercise. Significant dynamic LVOT
142	obstruction was documented by 2-dimensional and Doppler echocardiography or, in those
143	cases where echocardiography was insufficient, by invasive hemodynamic catheterization
144	with provocation.
145	2.2.3 Diagnosis of HFpEF
146	In our study, the diagnosis of HFpEF was determined by evaluating a combination of
147	symptoms, signs, left ventricular ejection fraction (LVEF), and concentrations of NT-proBNP.
148	Specifically, we followed the 2017 American Heart Association (AHA) criteria for
149	diagnosis ^[12] , which categorizes patients with LVEF \geq 50%, NT-proBNP \geq 800 pg/mL, and
150	symptoms or signs of heart failure as having HFpEF. Those who did not meet these criteria
151	were classified as non-HF.
152	2.2.4 Thyroid function test
153	Thyroid function was assessed after heart failure symptoms were controlled with regular oral
154	medication prior to discharge, rather than during the acute phase. The thyroid function test
155	was conducted at a median of 10 days after hospital admission. Blood samples were drawn
156	after a 12-hour fast and the serum levels of thyroid hormone and thyroid stimulating hormone
157	were measured using radioimmunoassay (Immulite 2000; Siemens, Germany).
158	2.3 Follow-up and endpoints.
159	Follow-up started at the time of the patient's first clinic contact after October 1, 2009. At
160	baseline, all patients were evaluated for the following characteristics: age, sex, NYHA

161	functional class, maximum left ventricular wall thickness (LVWT), maximum (Provo cable)
162	LVOT gradient, left ventricular function, atrial fibrillation, and conventional risk factors for
163	cardiac death.
164	The primary endpoints of this study were all-cause mortality and cardiac transplantation
165	during long-term follow-up. Mortality and adverse events were retrieved from hospital patient
166	records at the center where follow-up occurred, from civil service population registers, and
167	information provided by patients themselves and/or their general practitioners. Patients lost to
168	follow-up were censored upon the last contact with them. If no events occurred during
169	follow-up, the administrative censoring date was set for December 31, 2019.
170	2.4 Data Analysis
171	Statistical analysis was assessed with SPSS 27.0 statistical package for Windows, and R
172	software version 4.2.2 (R Foundation for Statistical Computing). All continuous variables are
173	presented as means \pm SD and analysis of variance was used to compare means across multiple
174	groups. The relationships between parametric variables were assessed by multiple linear
175	regression analysis. Initial differences in baseline characteristics between achieved treatment
176	groups were sought in bivariable analysis by using χ^2 tests, Fisher exact tests, Student <i>t</i> tests,
177	and Kruskal-Wallis analysis of variance. Cox proportional hazards model was used to
178	estimate the hazard ratio (HR). Kaplan-Meier analysis was used to study the cumulative
179	survival of different groups. A P-value less than 0.05 was considered statistically significant.
180	Restricted cubic spline (RCS) is a statistical method used to model nonlinear relationships
181	between a continuous predictor variable and an outcome variable. It is an extension of the
182	linear regression model and allows for flexible modeling of the relationship by using cubic

- 183 polynomial functions. In our study, we use the RCS method provides a flexible and powerful
- 184 way to model nonlinear relationships in R. We chose to use four knots, placed at the 10th,
- 185 50th, and 90th percentiles of the distribution of FT3 in our study population, to allow for a
- 186 flexible yet parsimonious modeling of the non-linear relationship between FT3 and
- 187 cardiovascular events. We assessed the overall fit of the model using the likelihood ratio test
- 188 and examined the shape of the spline function using graphical displays.

189 **2.5 Data and Resource Availability Statement**

- 190 The datasets generated during and/or analyzed in the current study are available from the
- 191 corresponding author upon reasonable request.
- 192 **3.Results**
- 193 The study population consisted of 992 HCM patients with HFpEF, with an average age of
- 194 53.60±13.83 years. The majority of patients were male (58.2%). Atrial fibrillation was present
- in 22.5% of patients, while 21.0% had unexplained syncope. The mean NT-proBNP level was
- 196 2278.18±1743.44 fmol/mL, and the mean FT3 level was 2.94±0.58 pg/mL.
- 197 Table 1. It shows the baseline clinical characteristics of the study population divided into the
- three tertiles based on the level of FT3. The total number of participants in the study was 992,
- 199 with Tertile 1 having 336 participants, Tertile 2 having 335 participants, and Tertile 3 having
- 200 321 participants. The mean age of the total population was 53.60±13.83 years, with Tertile 1
- being the oldest at 57.21±13.84 years and Tertile 3 being the youngest at 50.00±13.49 years
- 202 (p<0.001). Male participants made up the majority of the study population at 58.2%, with
- 203 Tertile 3 having the highest proportion of male participants at 76.0% (p<0.001). There were
- 204 no significant differences in body mass index (BMI), systolic and diastolic blood pressures,

205	and LV end-diastolic diameter among the three tertiles. However, participants in Tertile 3 had
206	a significantly higher level of FT3 than those in Tertile 1 and Tertile 2 (p<0.001). Regarding
207	comorbidities, atrial fibrillation was more prevalent in Tertile 3 than in Tertile 1 and Tertile 2
208	(p<0.001). On the other hand, NYHA Class III or IV was more common in Tertile 1 than in
209	Tertile 2 and Tertile 3 (p<0.001). In terms of medications, the use of beta-blockers,
210	ACEI/ARB, diuretics, and calcium antagonists did not differ significantly among the three
211	tertiles.

212 Table 2 shows the results of the univariate Cox analysis for all-cause mortality and cardiac 213 transplantation. The hazard ratios (HR) and 95% confidence intervals (CI) are reported for 214 each variable, along with the corresponding p-value. The results indicate that higher levels of 215 FT3 are associated with a lower risk of all-cause mortality and cardiac transplantation, with a 216 HR of 0.206 and a p-value of less than 0.001. Older age is associated with a higher risk of 217 mortality and transplantation, with a HR of 1.085 and a p-value of less than 0.001. Male 218 gender does not appear to be significantly associated with the risk of mortality and 219 transplantation, with a HR of 0.593 and a p-value of 0.108. Higher levels of NT-proBNP are 220 associated with a higher risk of mortality and transplantation, with a HR of 1.026 and a 221 p-value of less than 0.001. A history of atrial fibrillation is associated with a significantly 222 higher risk of mortality and transplantation, with a HR of 4.240 and a p-value of less than 223 0.001. A history of unexplained syncope does not appear to be significantly associated with 224 the risk of mortality and transplantation, with a HR of 1.460 and a p-value of 0.287. The 225 interventricular septal thickness does not appear to be significantly associated with the risk of 226 mortality and transplantation, with a HR of 1.001 and a p-value of 0.979.

227	In Table 3, two different models are presented: Model 1 and Model 2. Both models are
228	multivariate Cox regression models that examine the association between various factors and
229	all-cause mortality and cardiac transplantation. In Model 1, the factors included age, atrial
230	fibrillation, NT-proBNP (per 100 fmol/mL), and FT3 (pg/mL). The hazard ratio (HR) for age
231	was 1.062 (95% CI: 1.029, 1.096), indicating that for every one year increase in age, the risk
232	of all-cause mortality and cardiac transplantation increased by 6.2%. The HR for atrial
233	fibrillation was 2.142 (95% CI: 1.084, 4.234), indicating that patients with atrial fibrillation
234	had a 2.1 times higher risk of all-cause mortality and cardiac transplantation compared to
235	those without atrial fibrillation. The HR for NT-proBNP was 1.021 (95% CI: 1.007, 1.035),
236	indicating that for every 100 fmol/mL increase in NT-proBNP, the risk of all-cause mortality
237	and cardiac transplantation increased by 2.1%. The HR for FT3 was 0.374 (95% CI: 0.178,
238	0.788), indicating that for every 1 pg/mL increase in FT3, the risk of all-cause mortality and
239	cardiac transplantation decreased by 62.6%. In Model 2, the same factors were included as in
240	Model 1, but FT3 was analyzed as a categorical variable (tertiles). The reference group was
241	FT3 Tertial 3, and the HR for FT3 Tertial 2 was 0.480 (95% CI: 0.214, 1.074), indicating that
242	patients in the second tertile of FT3 levels had a 52.0% lower risk of all-cause mortality and
243	cardiac transplantation compared to those in the reference group. The HR for FT3 Tertial 1
244	was 0.336 (95% CI: 0.114, 0.988), indicating that patients in the first tertile of FT3 levels had
245	a 66.4% lower risk of all-cause mortality and cardiac transplantation compared to those in the
246	reference group. In addition, the HR for age, atrial fibrillation, and NT-proBNP remained
247	significant in Model 2. The HR for age was 1.040 (95% CI: 1.002, 1.079), indicating that for
248	every one year increase in age, the risk of all-cause mortality and cardiac transplantation

249	increased by 4.0%. The HR for atrial fibrillation was 3.399 (95% CI: 1.356, 8.517), indicating
250	that patients with atrial fibrillation had a 3.4 times higher risk of all-cause mortality and
251	cardiac transplantation compared to those without atrial fibrillation. The HR for NT-proBNP
252	was 1.023 (95% CI: 1.005, 1.041), indicating that for every 100 fmol/mL increase in
253	NT-proBNP, the risk of all-cause mortality and cardiac transplantation increased by 2.3%.
254	In Fig1, based on the KM survival curve, it seems that Group 1 had the worst long-term
255	prognosis, and there was a statistically significant difference in prognosis among the three
256	groups (log-rank test, p<0.001). It is important to note that the KM survival curve is a
257	graphical representation of the survival probability over time, and it allows for the
258	comparison of survival between different groups. In this case, it appears that patients with
259	lower FT3 levels had a worse prognosis than those with higher FT3 levels.
260	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the
260 261	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th
260 261 262	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th percentiles of the distribution of the FT3 in our study population, to allow for flexible yet
260 261 262 263	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th percentiles of the distribution of the FT3 in our study population, to allow for flexible yet parsimonious modeling of the non-linear relationship between the FT3 and cardiovascular
260 261 262 263 264	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th percentiles of the distribution of the FT3 in our study population, to allow for flexible yet parsimonious modeling of the non-linear relationship between the FT3 and cardiovascular events. We assessed the overall fit of the model using the likelihood ratio test and examined
260 261 262 263 264 265	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th percentiles of the distribution of the FT3 in our study population, to allow for flexible yet parsimonious modeling of the non-linear relationship between the FT3 and cardiovascular events. We assessed the overall fit of the model using the likelihood ratio test and examined the shape of the spline function using graphical displays. The RSC curve analysis showed a
260 261 262 263 264 265 266	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th percentiles of the distribution of the FT3 in our study population, to allow for flexible yet parsimonious modeling of the non-linear relationship between the FT3 and cardiovascular events. We assessed the overall fit of the model using the likelihood ratio test and examined the shape of the spline function using graphical displays. The RSC curve analysis showed a non-linear relationship between FT3 levels and prognosis. The RSC curve analysis revealed
260 261 262 263 264 265 266 267	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th percentiles of the distribution of the FT3 in our study population, to allow for flexible yet parsimonious modeling of the non-linear relationship between the FT3 and cardiovascular events. We assessed the overall fit of the model using the likelihood ratio test and examined the shape of the spline function using graphical displays. The RSC curve analysis showed a non-linear relationship between FT3 levels and prognosis. The RSC curve analysis revealed an "L" shape, indicating that as the FT3 level decreased, the prognosis of the patient gradually
260 261 262 263 264 265 266 267 268	In Fig2, we used restricted cubic splines to model the relationship between the FT3 and the risk of cardiovascular events. We chose to use four knots, placed at the 10th, 50th, and 90th percentiles of the distribution of the FT3 in our study population, to allow for flexible yet parsimonious modeling of the non-linear relationship between the FT3 and cardiovascular events. We assessed the overall fit of the model using the likelihood ratio test and examined the shape of the spline function using graphical displays. The RSC curve analysis showed a non-linear relationship between FT3 levels and prognosis. The RSC curve analysis revealed an "L" shape, indicating that as the FT3 level decreased, the prognosis of the patient gradually deteriorated. The critical value of FT3 was 2.885 pg/mL.

269 4. Discussion

270

Summary of the main findings This study investigated the prognostic value of FT3 in

271	Hypertrophic cardiomyopathy patients with HFpEF. The study found that lower FT3 levels
272	were associated with a higher risk of all-cause mortality and cardiac transplantation. The
273	multivariate analysis showed that FT3 was an independent prognostic factor after adjusting
274	for other clinical factors. The KM survival curve analysis showed that patients with lower
275	FT3 levels had worse long-term prognosis. Additionally, the RSC curve analysis showed an
276	"L" shaped relationship between FT3 levels and prognosis, with a critical value of
277	FT3=2.885.

Comparison with previous studies Our findings are consistent with previous studies that have reported an association between low FT3 levels and poor outcomes in patients with heart failure^[13,14]. However, our study is unique in that it used a large sample size, included various clinical factors in the analysis, and used RSC curve analysis to explore the non-linear relationship between FT3 and prognosis.

Interpretation of the results the results suggest that FT3 is a valuable prognostic factor for patients with heart failure. Lower FT3 levels are associated with worse outcomes and may be used to identify high-risk patients who require closer monitoring and more aggressive treatment. The non-linear relationship between FT3 and prognosis suggests that a critical value of FT3 may exist, below which the risk of adverse outcomes significantly increases.

Clinical implications and potential applications the identification of FT3 as a prognostic factor has important clinical implications for the management of heart failure. Clinicians should consider measuring FT3 levels in patients with heart failure to assess their risk of adverse outcomes. Additionally, our findings suggest that interventions to optimize FT3 levels may improve the prognosis of patients with heart failure.

There is growing evidence suggesting that thyroid hormones play a critical role in regulating cardiovascular function. In particular, thyroid hormone deficiency, also known as hypothyroidism, has been associated with a variety of cardiovascular diseases, including heart failure. Conversely, excess thyroid hormone, or hyperthyroidism, has also been linked to adverse cardiovascular outcomes, such as atrial fibrillation and sudden cardiac death.

The exact mechanisms by which thyroid hormones influence cardiovascular function are complex and not fully understood. It is known that thyroid hormones affect almost every aspect of cardiac function, including cardiac contractility, heart rate, and rhythm, as well as the structure and function of the blood vessels^[15,16]. Thyroid hormones also have profound effects on the metabolism of lipids and carbohydrates, which can further impact cardiovascular health^[17].

One of the proposed mechanisms by which thyroid hormones affect the prognosis of heart failure is through their influence on the sympathetic nervous system^[18]. Thyroid hormones are known to enhance sympathetic activity, which can increase heart rate and blood pressure, as well as promote cardiac hypertrophy and remodeling. These changes can ultimately lead to the development and progression of heart failure^[19].

309 Another possible mechanism is the effect of thyroid hormones on the 310 renin-angiotensin-aldosterone system (RAAS), which is a key regulator of blood pressure and 311 fluid balance in the body^[18]. Thyroid hormones have been shown to stimulate the RAAS, 312 which can lead to sodium and water retention and exacerbate the symptoms of heart failure.

In addition, thyroid hormones have been shown to directly affect the expression of genesinvolved in cardiac remodeling and fibrosis. In particular, excess thyroid hormone has been

315 associated with increased expression of genes involved in collagen synthesis and deposition,

316 which can lead to the development of myocardial fibrosis and impaired cardiac function.

317 Overall, the underlying mechanisms by which thyroid hormones influence the prognosis 318 of heart failure are complex and multifaceted. Further research is needed to fully elucidate 319 these mechanisms and to identify potential therapeutic targets for improving the outcomes of 320 patients with heart failure.

321 Limitations of the study

This study has several limitations. It was a retrospective study and subject to biases inherent in such studies. Future directions for research Future research should explore the mechanisms by which FT3 affects the prognosis of patients with heart failure. Additionally, prospective studies with larger sample sizes and multiple centers are needed to validate our findings and determine the optimal cut-off value for FT3 in identifying high-risk patients. Finally, interventional studies are needed to investigate the effect of interventions to optimize FT3 levels on the prognosis of patients with heart failure.

329 Clinical recommendations

Based on our findings, it is recommended that clinicians assess FT3 levels in Hypertrophic cardiomyopathy patients with HFpEF, in addition to other established prognostic factors such as age, atrial fibrillation, and NT-proBNP. Patients with low FT3 levels should be closely monitored for adverse outcomes and may benefit from targeted interventions to improve their thyroid function. Additionally, our study highlights the importance of identifying and addressing potentially modifiable factors, such as thyroid dysfunction, in the management of Hypertrophic cardiomyopathy patients with HFpEF.

337 Conclusion

cardiomyopathy patients with HFpEF, and the non-linear predictive value of FT3 prognosis is presented in an "L" shape, with a critical value of FT3=2.885. These findings important for clinicians to identify high-risk patients and adjust treatment strate accordingly. These findings have important implications for identifying high-risk pati who may benefit from early intervention and monitoring. Clinicians should cons measuring FT3 levels in patients with heart failure and monitoring them closely for adv outcomes. Future research should explore the underlying mechanisms linking FT3 levels adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and m diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progno factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights	338	In conclusion, our study found that FT3 is an independent prognostic factor in Hypertrophic
prognosis is presented in an "L" shape, with a critical value of FT3=2.885. These findings important for clinicians to identify high-risk patients and adjust treatment strate accordingly. These findings have important implications for identifying high-risk pati who may benefit from early intervention and monitoring. Clinicians should cons measuring FT3 levels in patients with heart failure and monitoring them closely for adv outcomes. Future research should explore the underlying mechanisms linking FT3 levels adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progno factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights	339	cardiomyopathy patients with HFpEF, and the non-linear predictive value of FT3 for
 important for clinicians to identify high-risk patients and adjust treatment strate accordingly. These findings have important implications for identifying high-risk pati who may benefit from early intervention and monitoring. Clinicians should cons measuring FT3 levels in patients with heart failure and monitoring them closely for adv outcomes. Future research should explore the underlying mechanisms linking FT3 levels adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small samples the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and m diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	340	prognosis is presented in an "L" shape, with a critical value of FT3=2.885. These findings are
 accordingly. These findings have important implications for identifying high-risk patients who may benefit from early intervention and monitoring. Clinicians should cons measuring FT3 levels in patients with heart failure and monitoring them closely for adv outcomes. Future research should explore the underlying mechanisms linking FT3 levels adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small samples the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	341	important for clinicians to identify high-risk patients and adjust treatment strategies
 who may benefit from early intervention and monitoring. Clinicians should cons measuring FT3 levels in patients with heart failure and monitoring them closely for adv outcomes. Future research should explore the underlying mechanisms linking FT3 levels adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	342	accordingly. These findings have important implications for identifying high-risk patients
 measuring FT3 levels in patients with heart failure and monitoring them closely for adv outcomes. Future research should explore the underlying mechanisms linking FT3 levels adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	343	who may benefit from early intervention and monitoring. Clinicians should consider
 outcomes. Future research should explore the underlying mechanisms linking FT3 levels adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progree factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	344	measuring FT3 levels in patients with heart failure and monitoring them closely for adverse
 adverse cardiovascular outcomes and evaluate the effectiveness of interventions aime improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a prograd factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	345	outcomes. Future research should explore the underlying mechanisms linking FT3 levels and
 improving thyroid hormone levels in patients with heart failure. However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	346	adverse cardiovascular outcomes and evaluate the effectiveness of interventions aimed at
However, this study has several limitations, including the relatively small sample s the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights	347	improving thyroid hormone levels in patients with heart failure.
the lack of information on potential confounding factors, and the limited generalizabilit the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights	348	However, this study has several limitations, including the relatively small sample size,
the results. Future studies with larger sample sizes, more comprehensive data, and n diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights	349	the lack of information on potential confounding factors, and the limited generalizability of
 diverse populations are needed to further validate our findings and explore the underly mechanisms. Overall, our study highlights the importance of considering FT3 as a progra factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights 	350	the results. Future studies with larger sample sizes, more comprehensive data, and more
mechanisms. Overall, our study highlights the importance of considering FT3 as a prografactor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights	351	diverse populations are needed to further validate our findings and explore the underlying
353 factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights	352	mechanisms. Overall, our study highlights the importance of considering FT3 as a prognostic
	353	factor in Hypertrophic cardiomyopathy patients with HFpEF and provides new insights into

- the management of this condition.
- 355 Consent for publication
- 356 All authors have approved the final manuscript for publication.

357 Availability of data and materials.

358 Not applicable.

359 Funding.

360	This w	vork was supported by: National Key R&D Program of China (2020YFC2004705), National
361	Natura	al Science Foundation of China (81825003, 91957123, 82270376), CAMS Innovation Fund
362	for M	edical Sciences (2022-I2M-C&T-B-119, 2021-I2M-5-003), Beijing Nova Program from
363	Beijin	g Municipal Science & Technology Commission(Z201100006820002), CSC Special Fund
364	for Cli	inical Research (CSCF2021A04).
365	Autho	or Contributions. X.B conducted statistical analyses and collaborated on drafting the
366	manus	cript. X.B, J.G, K.Z, W.X.L, W.Y.W, C.S and Y.D.T reviewed and edited the manuscript and
367	contril	puted to the discussion. W.Y.W, C.S and Y.D.T. obtained funding, conceived the research,
368	and dr	rafted the manuscript. All authors approved the final version of the manuscript. X.B is the
369	guarar	ntor of this work and, as such, had full access to all of the data in the study and takes
370	respon	sibility for the integrity of the data and the accuracy of the data analysis.
371	Ackno	owledgments.
372	The au	thors thank all the investigators and subjects who participated in this project.
373		
374	Refer	ences :
375	[1]	Gerdes AM, Ojamaa K. Thyroid Hormone and Cardioprotection[J]. Compr Physiol,
376		2016, 6(3): 1199-1219. doi: 10.1002/cphy.c150012
377	[2]	Fukuyama K, Ichiki T, Imayama I, et al. Thyroid hormone inhibits vascular remodeling
378 379 380		through suppression of cAMP response element binding protein activity[J]. Arterioscler Thromb Vasc Biol, 2006, 26(9): 2049-2055. doi: 10.1161/01.ATV.0000233358.87583.01
381	[3]	Wang JJ, Zhuang ZH, Shao CL, et al. Assessment of causal association between
382 383		thyroid function and lipid metabolism: a Mendelian randomization study[J]. Chin Med J (Engl), 2021, 134(9): 1064-1069. doi: 10.1097/cm9.0000000000001505

384	[4]	Wang WY, Tang YD, Yang M, et al. Free triiodothyronine level indicates the degree of
385 386 387		myocardial injury in patients with acuteST-elevation myocardial infarction[J]. ChinMedJ(Engl),2013,126(20):3926-3929.doi:10.3760/cma.j.issn.0366-6999.20130087
388	[5]	Zhang K, Meng X, Wang W, et al. Prognostic Value of Free Triiodothyronine Level in
389 390		Patients With Hypertrophic Obstructive Cardiomyopathy[J]. J Clin Endocrinol Metab, 2018, 103(3): 1198-1205. doi: 10.1210/jc.2017-02386
391	[6]	Wang W, Guan H, Gerdes AM, et al. Thyroid Status, Cardiac Function, and Mortality in
392 393		Patients With Idiopathic Dilated Cardiomyopathy[J]. J Clin Endocrinol Metab, 2015, 100(8): 3210-3218. doi: 10.1210/jc.2014-4159
394	[7]	Dillmann W. Cardiac hypertrophy and thyroid hormone signaling[J]. Heart Fail Rev,
395		2010, 15(2): 125-132. doi: 10.1007/s10741-008-9125-7
396	[8]	Ojamaa K. Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy[J].
397		Vascul Pharmacol, 2010, 52(3-4): 113-119. doi: 10.1016/j.vph.2009.11.008
398	[9]	Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis
399 400 401 402		and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 124(24): e783-831. doi: 10.1161/CIR.0b013e318223e2bd
403	[10]	Authors/Task Force m, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on
404 405 406 407		diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35(39): 2733-2779. doi: 10.1093/eurheartj/ehu284
408	[11]	Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of
409 410		Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2022, 79(4): 372-389. doi: 10.1016/j.jacc.2021.12.002
411	[12]	Chow SL, Maisel AS, Anand I, et al. Role of Biomarkers for the Prevention,
412 413 414		Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association[J]. Circulation, 2017, 135(22): e1054-e1091. doi: 10.1161/cir.000000000000490
415	[13]	De Matteis G, Covino M, Burzo ML, et al. Prognostic role of hypothyroidism and low
416 417		free-triiodothyronine levels in patients hospitalized with acute heart failure[J]. Intern Emerg Med, 2021, 16(6): 1477-1486. doi: 10.1007/s11739-020-02582-y

- 418 [14] Sato Y, Yoshihisa A, Kimishima Y, et al. Low T3 Syndrome Is Associated With High
- 419 Mortality in Hospitalized Patients With Heart Failure[J]. J Card Fail, 2019, 25(3):
 420 195-203. doi: 10.1016/j.cardfail.2019.01.007
- 421 [15] Grais IM, Sowers JR. Thyroid and the heart[J]. Am J Med, 2014, 127(8): 691-698. doi:
- 422 10.1016/j.amjmed.2014.03.009
- 423 [16] Cappola AR, Desai AS, Medici M, et al. Thyroid and Cardiovascular Disease
 424 Research Agenda for Enhancing Knowledge, Prevention, and Treatment[J].
 425 Circulation, 2019. doi: 10.1161/circulationaha.118.036859
- 426 [17] Yamakawa H, Kato TS, Noh JY, et al. Thyroid Hormone Plays an Important Role in
- 427 Cardiac Function: From Bench to Bedside[J]. Front Physiol, 2021, 12: 606931. doi:
 428 10.3389/fphys.2021.606931
- 429 [18] Martinez F. Thyroid hormones and heart failure[J]. Heart Fail Rev, 2016, 21(4):
- 430 361-364. doi: 10.1007/s10741-016-9556-5
- 431 [19] Borovac JA, D'Amario D, Bozic J, et al. Sympathetic nervous system activation and
- 432 heart failure: Current state of evidence and the pathophysiology in the light of novel
 433 biomarkers[J]. World J Cardiol, 2020, 12(8): 373-408. doi: 10.4330/wjc.v12.i8.373

434





Fig2. Restricted Cubic Splines (RCS) of the relationship between the FT3 and the risk of all-cause mortality and cardiac transplantation.

	Total (n=992)	Tertile 1 (n=336)	Tertile 2 (n=335)	Tertile 3 (n=321)	P-value
Age, y	53.60±13.83	57.21±13.84	53.60±13.30	50.00±13.49	< 0.001
Male, n (%)	577 (58.2%)	132 (39.3%)	201 (60.0%)	244 (76.0%)	< 0.001
BMI (kg/m^2)	25.42±4.25	25.01±3.59	25.51±4.92	25.72±4.07	0.177
Systolic BP (mmHg)	$121.58{\pm}18.47$	122.17±18.06	120.84±19.27	121.79 ± 18.05	0.716
Diastolic BP (mmHg)	74.12±12.27	73.97±11.98	74.01±13.15	74.37±11.59	0.927
NT-proBNP (fmol/mL)	2278.18±1743.44	2760.72±2024.43	2153.81±1610.95	1930.14±1454.51	< 0.001
FT3 (pg/mL)	$2.94{\pm}0.58$	2.456±0.29	$2.93{\pm}0.09$	$3.44{\pm}0.69$	< 0.001
Atrial fibrillation, n (%)	223 (22.5%)	55 (16.4%)	21 (6.2%)	31 (9.7%)	< 0.001
Non- sustained ventricular tachycardia, n (%)	52 (5.2%)	19 (5.7%)	15 (4.5%)	18(5.6%)	0.742
NYHA Class III or IV, n (%)	128 (12.9%)	63 (18.8%)	35 (10.4%)	30 (9.4%)	< 0.001
Unexplained syncope, n (%)	208(21.0%)	57(17.0%)	91(27.2%)	60(18.7%)	0.002
Echocardiography					
Interventricular septal	20.23±5.19	19.51±4.86	20.57±5.68	20.56±4.90	0.038
LV end-diastolic diameter	42.92±5.91	42.86±5.80	42.64±6.33	43.30±5.53	0.464
LV ejection fraction (%)	64.55±6.10	63.97±6.58	64.38±6.00	65.30±5.65	0.054

Table 1. Baseline clinical characteristics of the study population divided into the three tertiles based on the level of FT3.

51.00±13.42	46.17±15.48	52.73±12.59	53.96±12.29	0.090
603 (60.8%)	205 (61.0%)	199 (59.4%)	199 (61.9%)	0.465
170 (17.1%)	63 (18.8%)	60 (17.9%)	47 (14.6%)	0.449
148 (19.0%)	72 (21.4%)	55 (16.4%)	61 (19.0%)	0.120
205 (20.7%)	84 (25.0%)	58 (17.3%)	63 (19.6%)	0.091
	51.00±13.42 603 (60.8%) 170 (17.1%) 148 (19.0%) 205 (20.7%)	51.00±13.42 46.17±15.48 603 (60.8%) 205 (61.0%) 170 (17.1%) 63 (18.8%) 148 (19.0%) 72 (21.4%) 205 (20.7%) 84 (25.0%)	51.00±13.42 46.17±15.48 52.73±12.59 603 (60.8%) 205 (61.0%) 199 (59.4%) 170 (17.1%) 63 (18.8%) 60 (17.9%) 148 (19.0%) 72 (21.4%) 55 (16.4%) 205 (20.7%) 84 (25.0%) 58 (17.3%)	51.00±13.42 46.17±15.48 52.73±12.59 53.96±12.29 603 (60.8%) 205 (61.0%) 199 (59.4%) 199 (61.9%) 170 (17.1%) 63 (18.8%) 60 (17.9%) 47 (14.6%) 148 (19.0%) 72 (21.4%) 55 (16.4%) 61 (19.0%) 205 (20.7%) 84 (25.0%) 58 (17.3%) 63 (19.6%)

Values are mean \pm SD or n (%).

Abbreviation: BMI, body mass index; NT-proBNP, N-terminal pro-brain natriuretic peptide; BP, blood pressure; NYHA, New York Heart Association; LV, left

ventricle; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.

	HR (95% CI)	P value
FT3 (pg/mL)	0.206 (0.106, 0.402)	< 0.001
Age, y	1.085(1.053, 1.118)	< 0.001
Male, n (%)	0.593(0.314, 1.122)	0.10.8
NT-proBNP (per 100 fmol/mL)	1.026(1.015, 1.037)	< 0.001
Atrial fibrillation, n (%)	4.240 (2.235, 8.044)	< 0.001
Unexplained syncope, n (%)	1.460(0.724, 2.944)	0.290
Interventricular septal thickness (mm)	1.001 (0.948, 1.056)	0.980

Table 2. Univariate Cox Analysis for All-Cause Mortality and Cardiac transplantation

Abbreviations are listed in Table 1.

	Model 1		Model 2		
	HR (95% CI)	P value	HR (95% CI)	P value	
Age, y	1.062 (1.029, 1.096)	< 0.001	1.040 (1.002, 1.079)	0.037	
Atrial fibrillation	2.142 (1.084, 4.234)	0.028	3.399 (1.356, 8.517)	0.009	
NT-proBNP (per 100 fmol/ml)	1.021 (1.007, 1.035)	0.003	1.023 (1.005,1.041)	0.012	
FT3 ((pg/mL)	0.374 (0.178, 0.788)	0.010			
FT3 Tertial 3			1 (reference)		
FT3 Tertial 2			0.480 (0.214, 1.074)	0.074	
FT3 Tertial 1			0.336(0.114, 0.988)	0.048	

Table 3. Multivariate Cox Analysis for All-Cause Mortality and Cardiac transplantation

Multivariate Cox model selected by a stepwise method with factors that were significant in the univariate analysis and established risk factors for prognosis (age, Atrial fibrillation, NT-proBNP). Model 1 was constructed based on inclusion of FT3 as continuous variable; Model 2 was constructed based on inclusion of FT3 as Categorical variable.